Replies to post #6285 on Navidea Biopharmaceuticals Inc (NAVB)

[Cave In Temptor]

Regarding PM, there are 3 things we know and 1 we don't:
-- High level change is ongoing at PM
(2013 10k pp 60) Michael Goldberg has served as a Managing Partner of Montaur Capital Partners since January 2007.
(2013 10k pp 84) Dr. Goldberg has advised the Company that he is in the process of completing his withdrawal from any ownership or management position with Platinum, but he has not advised the Company of the terms or timing of such separation.

-- PM's average cost
(13D/A dated Nov 13, 2013) 10,073 CS for $9.9 M and 26,199 (CS in Ser B) for $12.1 M
So, CS at $0.61 average.

-- PM has been selling since Nov 2013
(2013 10k pp 84) As of February 28, 2014, PM owned 14,185 CS and 11,128 CS in Ser B
So 10,959 sold Nov 13, 13- Feb 28, 14.

-- What we don't know, and alas is most important, is why PM is cashing out now.
One could assume by default this is Navidea-related and thus heralding horribly bad times.
We should also consider this could be Navidea-independent, linked to PM's fund-raising (cashing-in to generate ROI), fund-winding (cashing-out to pay LPs), or plain change of strategy.

JMHO